The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| SLRX | -84.71% | -99.81% | -71.51% | -100% |
| S&P | +16.9% | +95.99% | +14.39% | +128% |
Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company, which engages in the development of treatments for cancers with high, unmet medical need. Its pipeline includes SP-3164, a targeted protein degrader and seclidemstat (SP-2577), a targeted protein inhibitor. The company was founded in February 2014 and is headquartered in Houston, TX.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.00M | 0.0% |
| Market Cap | $1.91M | 48.5% |
| Market Cap / Employee | $0.95M | 0.0% |
| Employees | 2 | 0.0% |
| Net Income | -$0.96M | 32.8% |
| EBITDA | -$0.96M | 34.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $0.79M | -75.7% |
| Accounts Receivable | $0.00M | 0.0% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | 0.0% |
| Short Term Debt | $0.00M | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -206.34% | -123.5% |
| Return On Invested Capital | -195.32% | -60.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$0.86M | 19.6% |
| Operating Free Cash Flow | -$0.86M | 19.6% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.71 | 1.75 | 25.37 | -2.30 | -753.11% |
| Price to Tangible Book Value | 5.83 | 13.60 | 10.78 | 452.22 | 8472.00% |
| Enterprise Value to EBITDA | 1.10 | -0.30 | 0.25 | -1.15 | -191.29% |
| Return on Equity | -110.9% | -164.0% | -300.2% | -660.4% | 451.09% |
| Total Debt | $0.33M | $0.22M | $0.11M | $0.00M | - |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
